Molecular Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Chemical and Biological Aspects of Inflammation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kokkinakis, D. M.
Right arrow Articles by Chada, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kokkinakis, D. M.
Right arrow Articles by Chada, S.
Molecular Cancer Research 4:575-589 (2006)
© 2006 American Association for Cancer Research


DNA Damage and Cellular Stress Responses

Mitotic Arrest, Apoptosis, and Sensitization to Chemotherapy of Melanomas by Methionine Deprivation Stress

Demetrius M. Kokkinakis1,4, Anthony G. Brickner2,3,4, John M. Kirkwood2,4, XiaoYan Liu4, Jason E. Goldwasser4, Anastasiya Kastrama4, Cindy Sander2, Dora Bocangel5 and Sunil Chada5

Departments of 1 Pathology, 2 Medicine, and 3 Immunology and 4 Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania and 5 Introgen Therapeutics, Inc., Houston, Texas

Requests for reprints: Demetrius M. Kokkinakis, Hillman Cancer Center Research Pavillion, Room G12.e, 5117 Centre Avenue, Pittsburgh, PA 15213. Phone: 412-585-0833; Fax: 724-625-3036. E-mail: kokkinakisdm{at}thiogenics.com

Methionine deprivation stress (MDS) eliminates mitotic activity in melanoma cells regardless of stage, grade, or TP53 status, whereas it has a negligible effect on normal skin fibroblasts. In most cases, apoptosis accounts for the elimination of up to 90% of tumor cells from the culture within 72 hours after MDS, leaving a scattered population of multinucleated resistant cells. Loss of mitosis in tumor cells is associated with marked reduction of cyclin-dependent kinase (CDK) 1 transcription and/or loss of its active form (CDK1-P-Thr161), which is coincident with up-regulation of CDKN1A, CDKN1B, and CDKN1C (p21, p27, and p57). Expression of the proapoptotic LITAF, IFNGR, EREG, TNFSF/TNFRSF10 and TNFRSF12, FAS, and RNASEL is primarily up-regulated/induced in cells destined to undergo apoptosis. Loss of Aurora kinase B and BIRC5, which are required for histone H3 phosphorylation, is associated with the accumulation of surviving multinucleated cells. Nevertheless, noncycling survivors of MDS are sensitized to temozolomide, carmustin, and cisplatin to a much greater extent than normal skin fibroblasts possibly because of the suppression of MGMT/TOP1/POLB, MGMT/RAD52/RAD54, and cMET/RADD52, respectively. Sensitivity to these and additional genotoxic agents and radiation may also be acquired due to loss of cMET/OGG1, reduced glutathione reductase levels, and a G2-phase block that is a crucial step in the damage response associated with enhancement of drug toxicity. Although the genes controlling mitotic arrest and/or apoptosis in response to low extracellular methionine levels are unknown, it is likely that such control is exerted via the induction/up-regulation of tumor suppressors/growth inhibitor genes, such as TGFB, PTEN, GAS1, EGR3, BTG3, MDA7, and the proteoglycans (LUM, BGN, and DCN), as well as the down-regulation/loss of function of prosurvival genes, such as NF{kappa}B, MYC, and ERBB2. Although MDS targets several common genes in tumors, mutational variability among melanomas may decide which metabolic and signal transduction pathways will be activated or shutdown. (Mol Cancer Res 2006;4(8):575–89)




This article has been cited by other articles:


Home page
Cancer Res.Home page
D. Krige, L. A. Needham, L. J. Bawden, N. Flores, H. Farmer, L. E.C. Miles, E. Stone, J. Callaghan, S. Chandler, V. L. Clark, et al.
CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells
Cancer Res., August 15, 2008; 68(16): 6669 - 6679.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
L. Milani, M. Gupta, M. Andersen, S. Dhar, M. Fryknas, A. Isaksson, R. Larsson, and A.-C. Syvanen
Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells
Nucleic Acids Res., March 12, 2007; 35(5): e34 - e34.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.